
Harvard Bioscience, Inc.: updates and filings
Price
$8.70
November 20, 2026Market cap $39M
What Ploutos Investor adds for Harvard Bioscience
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 10, 2026next Feb 11, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
March 2026
February 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 10, 2026Regulation FD disclosureForm8-K
- Nov 10, 2026Results of operationsForm8-K
- Sep 22, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 11, 2026Regulation FD disclosureForm8-K
- Aug 11, 2026Results of operationsForm8-K
- Jun 10, 2026Shares registered for employeesFormS-8
- Jun 2, 2026Officer or director change, shareholder voteForm8-K
- May 27, 2026Conflict minerals reportFormSD
- May 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 12, 2026Regulation FD disclosureForm8-K
- May 12, 2026Results of operationsForm8-K
- Apr 21, 2026Additional annual meeting materialFormDEFA14A
- Apr 21, 2026Annual meeting proxy statementFormDEF 14A
- Mar 23, 2026Over-5% holder statement (active)FormSCHEDULE 13D
- Mar 17, 2026Regulation FD disclosureForm8-K
- Mar 13, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 12, 2026Results of operationsForm8-K
- Mar 10, 2026Officer or director changeForm8-K
- Mar 6, 2026Shareholder vote, Regulation FD disclosure, other material eventsForm8-K
- Feb 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 10, 2026Results of operationsForm8-K
- Feb 9, 2026FilingFormEFFECT
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 10, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 10, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 10, 2026 | 8-K | Results of operations | Document |
| Sep 22, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 11, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 11, 2026 | 8-K | Results of operations | Document |
| Jun 10, 2026 | S-8 | Shares registered for employees | Document |
| Jun 2, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 27, 2026 | SD | Conflict minerals report | Document |
| May 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 12, 2026 | 8-K | Regulation FD disclosure | Document |
| May 12, 2026 | 8-K | Results of operations | Document |
| Apr 21, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 21, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 23, 2026 | SCHEDULE 13D | Over-5% holder statement (active) | Document |
| Mar 17, 2026 | 8-K | Regulation FD disclosure | Document |
| Mar 13, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 12, 2026 | 8-K | Results of operations | Document |
| Mar 10, 2026 | 8-K | Officer or director change | Document |
| Mar 6, 2026 | 8-K | Shareholder vote, Regulation FD disclosure, other material events | Document |
| Feb 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 10, 2026 | 8-K | Results of operations | Document |
| Feb 9, 2026 | EFFECT | Filing | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Sep 18, 2000.
The full analysis
What do Harvard Bioscience's filings show?
The filings are where every one of Harvard Bioscience's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.